SCHEMBL6462346

SCHEMBL6462346

CCCNC(=O)Cc1c(C)n(C(=O)c2ccc(Br)cc2)c2cc(F)c(O)cc12.CCNC(=O)Cc1c(C)n(C(=O)c2ccc(Br)cc2)c2cc(F)c(O)cc12.CNC(=O)Cc1c(C)n(C(=O)c2ccc(Br)cc2)c2cc(F)c(O)cc12.Cc1c(CC(=O)NC(C)C)c2cc(O)c(F)cc2n1C(=O)c1ccc(Br)cc1.Cc1c(CC(=O)O)c2cc(O)c(F)cc2n1C(=O)c1ccc(Br)cc1.Cc1c(CC(N)=O)c2cc(O)c(F)cc2n1C(=O)c1ccc(Br)cc1

nearest known ligand 0.38

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 13/20 0.38
AKR1C3 P42330 3/20 0.38
AKR1C2 P52895 3/20 0.38
PTGS1 P23219 2/20 0.37
PLA2G2A P14555 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6460949 0.95 AKR1C3 (0.41) PTGS2AKR1C3AKR1C2PTGS1PLA2G2A
SCHEMBL6462577 0.95 AKR1C3 (0.44) PTGS2AKR1C3AKR1C2PTGS1PLA2G2A
SCHEMBL6460909 0.93 PTGS2 (0.46) PTGS2AKR1C3AKR1C2PTGS1
SCHEMBL6462135 0.93 PTGS2 (0.39) PTGS2AKR1C3AKR1C2PTGS1
SCHEMBL6462352 0.92 AKR1C3 (0.45) PTGS2AKR1C3AKR1C2PTGS1PLA2G2A
SCHEMBL6467633 0.92 PTGS2 (0.42) PTGS2AKR1C3AKR1C2PTGS1PLA2G2A
SCHEMBL6460882 0.92 PTGS2 (0.40) PTGS2AKR1C3AKR1C2PLA2G2A
SCHEMBL6462586 0.91 PTGS2 (0.39) PTGS2AKR1C3AKR1C2PTGS1
SCHEMBL6466305 0.91 PTGS2 (0.39) PTGS2AKR1C3AKR1C2PTGS1
SCHEMBL6464766 0.90 AKR1C3 (0.41) PTGS2AKR1C3AKR1C2PTGS1PLA2G2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050032747-A1 COX-2 and FAAH inhibitors POLYMER CONCEPTS TECHNOLOGIES PBY, INC. 2005-02-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050032747-A1 COX-2 and FAAH inhibitors FAAH2, FAAH, PTGS2 PTGS2 3/4885AKR1C3 585/4885AKR1C2 342/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.